CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RIVe-CLL/SLL)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03639324
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:24.662527+00:00
- Published At
- 2021-11-09T00:00:00+00:00
- Record Updated At
- 2021-11-09
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Chronic Lymphocytic Leukemia", "CLL", "Relapsed CLL", "Refractory Chronic Lymphocytic Leukemia", "Relapsed Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "SLL", "Relapsed Small Lymphocytic Lymphoma", "Refractory Small Lymphocytic Lymphoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-11-09"- protocolSection.identificationModule.nctId
"NCT03639324"- protocolSection.identificationModule.officialTitle
"Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RIVe-CLL/SLL)"- protocolSection.statusModule.overallStatus
"WITHDRAWN"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.